Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT00396110

Collaborator

(none)

3,889

Enrollment

Study Details

Study Description

Brief Summary

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Condition or Disease	Intervention/Treatment	Phase
Hypercholesterolemia Coronary Heart Disease

Study Design

Study Type:

Observational

Observational Model:

Defined Population

Time Perspective:

Prospective

Official Title:

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Study Start Date :

Feb 1, 2003

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin